Under construction – not a live service
Sign in
Not yet taking people in ChinaPhase 3

Tenecteplase for Minor but Disabling Stroke With a Blocked Large Artery

Tests tenecteplase against standard medicine in adults with minor, disabling stroke.

Plain-language title generated from the registry record
Registry title: Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window

Key facts

Where
Anshan, Benxi, Chaoyang, Dalian, Dandong, Fushun, Fuxin, Fuzhou, Huludao, Jinzhou, Liaoyang, Panjin, Shenyang, Tieling, Wafangdian, and Yingkou, ChinaSee the 30 sites
Phase
Phase 3

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a mild stroke that still causes disabling problems, caused by a blocked large brain artery, 4.5 to 24 hours after it began. It compares tenecteplase with standard medical management.

Age
18 years or older
Sex
Men and women can join.
Disease stage
Acute ischemic stroke with a mild score (NIHSS 2-5) but a disabling deficit, and a blocked large brain artery (internal carotid artery, or middle cerebral artery M1/M2 segment) shown on CTA or MRA. Brain bleeding must be ruled out by CT or MRI. Scans must show a core infarct volume < 70 ml, penumbra volume ≥ 15 ml and mismatch ratio ≥ 1.8.
Earlier treatment
Cannot have had heparin or oral anticoagulant therapy within 48 hours, or thrombin or factor Xa inhibitors.

Main reasons for not taking part

  • Disability before the stroke (pre-stroke mRS ≥ 2)
  • Stroke in the last 3 months, or earlier bleeding in the brain
  • Major surgery within the last 1 month
  • Blood pressure of 180/110 mmHg or higher
  • Pregnancy

Read by machine on 9 November 2026.

Where in China

  • Anshan Central HospitalAnshan, ChinaContact: Hongbo XiaoNo longer taking part
  • Anshan Changda HospitalAnshan, ChinaContact: Yulin SongNo longer taking part
  • Benxi Central HospitalBenxi, ChinaContact: Chengguang SongNo longer taking part
  • Chaoyang Central HospitalChaoyang, ChinaContact: Xiaomei HeNo longer taking part
  • Dalian Municipal Central Hospital Affiliated of Dalian University of TechnologyDalian, ChinaContact: Di LiNo longer taking part
  • Dandong Central HospitalDandong, ChinaContact: Ming SunNo longer taking part
  • Dandong First HospitalDandong, ChinaContact: Lishu WanNo longer taking part
  • Fushun Central HospitalFushun, ChinaContact: Yan YangNo longer taking part
  • Liaojian Group Fukuang General HospitalFushun, ChinaContact: Hong ZhangNo longer taking part
  • Fuxin People's HospitalFuxin, ChinaContact: Ying BaoNo longer taking part
  • Fujian Medical University Union HospitalFuzhou, ChinaContact: Wenhuo Chen, M.DNo longer taking part
  • Huludao Central HospitalHuludao, ChinaContact: Changming XuNo longer taking part
  • The First Affiliated Hospital of Jinzhou Medical UniversityJinzhou, ChinaContact: Li LiuNo longer taking part
  • Liaoyang Central HospitalLiaoyang, ChinaContact: Xinbin HaoNo longer taking part
  • Panjin Central HospitalPanjin, ChinaContact: Zhuo LiNo longer taking part
  • Central Hospital Affiliated to Shenyang Medical CollegeShenyang, ChinaContact: Runhui LiNo longer taking part
  • Liaoning Provincial People's HospitalShenyang, ChinaContact: Muhui LinNo longer taking part
  • Shenyang Fifth People's HospitalShenyang, ChinaContact: Jinchun WangNo longer taking part
  • Shenyang First People's HospitalShenyang, ChinaContact: Li LiNo longer taking part
  • Shenyang Fourth People's HospitalShenyang, ChinaContact: Chuansheng Zhao, M.DNo longer taking part
  • Shenyang Tenth People's HospitalShenyang, ChinaContact: Chuansheng Zhao, M.DNo longer taking part
  • Sujiatun District Central HospitalShenyang, ChinaContact: Hongxia ZhaoNo longer taking part
  • The Fourth Affiliated Hospital of China Medical UniversityShenyang, ChinaContact: Zhenwei HeNo longer taking part
  • The Second Affiliated Hospital of Shenyang Medical CollegeShenyang, ChinaContact: Yan DuNo longer taking part
  • Liaojian Group Tieling Coal General HospitalTieling, ChinaContact: Gaohua LiNo longer taking part
  • Tieling Central HospitalTieling, ChinaContact: Yong LiangNo longer taking part
  • Tieling County Central HospitalTieling, ChinaContact: Liying ShenNo longer taking part
  • Wafangdian Central HospitalWafangdian, ChinaContact: Wei LiNo longer taking part
  • Wafangdian Third People's HospitalWafangdian, ChinaContact: Renlin ZouNo longer taking part
  • Yingkou Central HospitalYingkou, ChinaContact: Dongqun LiNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
First Hospital of China Medical University
Trial code
NCT07476898
Record updated
17 March 2026
Original description
To verify the efficacy and safety of intravenous tenecteplase (TNK) in patients with disabling minor stroke and large vessel occlusion (LVO) within a 4.5-24 hour time window.Read full original descriptionShow less

A Multicenter, Randomized, Open-Label, Blinded-Endpoint Trial of Tenecteplase Versus Dual Antiplatelet Therapy in Mild Disabling Ischemic Stroke With Large Vessel Occlusion Beyond 4.5 Hours (TIME-MINOR Trial)

To verify the efficacy and safety of intravenous tenecteplase (TNK) in patients with disabling minor stroke and large vessel occlusion (LVO) within a 4.5-24 hour time window.

Inclusion: Male or female subjects (age ≥ 18 years); Diagnosis of acute ischemic stroke, with intracranial hemorrhage ruled out by CT or MRI; Time from stroke onset or last known well to randomization is 4.5 to 24 hours; NIHSS score 2-5 and meeting the definition of disabling deficit: complete hemianopia (NIHSS question 3 score ≥ 2); severe aphasia (NIHSS question 9 score ≥ 2); neglect (NIHSS question 11 score ≥ 1); any persistent limb weakness against gravity (NIHSS question 6 or 7 score ≥ 2); any functional deficit considered potentially disabling by the physician and patient, such as inability to perform basic activities of daily living (bathing, independent walking, toileting, personal hygiene, and eating) or return to work; LVO (internal carotid artery, middle cerebral artery M1/M2 segments) confirmed by CTA or MRA, including tandem lesions; Core infarct volume < 70 ml, ischemic penumbra volume ≥ 15 ml, and mismatch ratio ≥ 1.8, as shown by CTP or MRI+MRP; Written informed consent.

Exclusion: Major surgery within the last 1 month; Heparin or oral anticoagulant therapy within 48 hours; Thrombin or factor Xa inhibitors; Participation in any other investigational drug or device study within the last 3 months; Significant pre-stroke neurological deficit (pre-stroke mRS ≥ 2); History of stroke within the last 3 months; History of intracranial hemorrhage; Suspected subarachnoid hemorrhage; Severe illness with life expectancy < 3 months; Platelet count < 10⁵/mm³; Abnormal APTT; Blood glucose < 50 mg/dL (2.7 mmol/L); Intracranial tumor, vascular malformation, or aneurysm; Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg; Pregnancy; Patients deemed unsuitable for the registry study by the investigator.

ClinicalTrials.gov NCT07476898